Previous 10 | Next 10 |
Includes Full Exercise of Underwriters' Overallotment Option EDISON, NJ / ACCESSWIRE / November 30, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatm...
Gainers: AnPac Bio-Medical Science (ANPC) +97%.Mmtec (MTC) +79%.Newborn Acquisition (NBAC) +49%.Elys Game Technology (ELYS) +45%.WidePoint (WYY) +42%.ZK International (ZKIN) +39%.Cocrystal Pharma (COCP) +37%.Renalytix (RNLX) +31%.Tuniu (TOUR) +28%.Sierra Wireless (SWIR) +2...
Gainers: AnPac Bio-Medical Science (ANPC) +110%, Cocrystal Pharma (COCP) +56%, Renalytix AI (RNLX) +31%, Precigen (PGEN) +13%, Chiasma (CHMA) +11%.Losers: Hepion Pharmaceuticals (HEPA) -29%, Medigus (MDGS) -12%, Retractable Technologies (...
Hepion Pharmaceuticals (HEPA)-28% after prices equity offering at $1.50.Fuel Tech (FTEK) -25%.ECMOHO (MOHO) -24%.Ideanomics (IDEX) -17%.Nikola (NKLA) -15% on concerns over GM deal, gauntlet of stock.Blink Charging (BLNK) -12%.Li Auto (LI) -12% Chinese EV stocks ...
Hepion Pharmaceuticals (HEPA) has priced its public offering of 20M common shares at $1.50/share, for expected gross proceeds of ~$30M. Underwriters' over-allotment is an additional 3M shares. Net proceeds will be used to fund R&D activities, for working capital and other general corporat...
EDISON, NJ / ACCESSWIRE / November 24, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pri...
Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: B...
- Interim DSMB review at the midpoint of the first dose cohort affirmed no safety or tolerability concerns with 75 mg of CRV431 in NASH patients - - DSMB recommended the AMBITION study continue with 225 mg CRV431 dose cohort - - Clinically significant reductions observed in the liv...
EDISON, NJ / ACCESSWIRE / November 17, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced tha...
EDISON, NJ / ACCESSWIRE / November 12, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced tha...
News, Short Squeeze, Breakout and More Instantly...
Hepion Pharmaceuticals Inc. Company Name:
HEPA Stock Symbol:
NASDAQ Market:
Hepion Pharmaceuticals Inc. Website:
Gaucho Group Holdings Inc. (VINO) is expected to report for Q1 2024 Tosoh Corporation (TOSCF) is expected to report for Q4 2024 Adidas AG ADR - Level I (ADDYY) is expected to report $0.69 for Q1 2024 MicroCloud Hologram Inc. (HOLO) is expected to report for Q1 2024 Universal Enter...
Jet.AI Inc. (JTAI) is expected to report for Q1 2024 Forian Inc. (FORA) is expected to report $-0.02 for Q1 2024 Square Enix Holdings Co. Ltd (SQNXF) is expected to report for Q4 2024 Qutoutiao Inc. (QTT) is expected to report for Q4 2023 Molecular Partners AG (MOLN) is expected t...
A look at the top 10 most actives in the United States AGBA Group Holding Limited (AGBA) rose 100.0% to $2.5 on volume of 201,539,290 shares PROSHARES TRUST (SQQQ) fell 2.9% to $12.47 on volume of 154,254,858 shares Tesla Inc. (TSLA) fell 3.4% to $142.05 on volume of 106,267,579 shares ...